Vectura Group PLC (VEC) Price Target Cut to GBX 170 by Analysts at Numis Securities Ltd
Vectura Group PLC (LON:VEC) had its price target trimmed by Numis Securities Ltd from GBX 205 ($2.70) to GBX 170 ($2.24) in a research note issued to investors on Thursday. The firm currently has a buy rating on the stock.
Other analysts have also recently issued reports about the company. Shore Capital restated a buy rating on shares of Vectura Group PLC in a report on Thursday. Citigroup Inc. dropped their target price on Vectura Group PLC from GBX 200 ($2.63) to GBX 180 ($2.37) and set a buy rating for the company in a report on Monday, September 18th. Peel Hunt restated a hold rating and issued a GBX 160 ($2.10) target price on shares of Vectura Group PLC in a report on Wednesday, August 16th. J P Morgan Chase & Co dropped their target price on Vectura Group PLC from GBX 210 ($2.76) to GBX 180 ($2.37) and set an overweight rating for the company in a report on Thursday, September 21st. Finally, Panmure Gordon restated a buy rating on shares of Vectura Group PLC in a report on Wednesday, August 30th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average target price of GBX 189.67 ($2.49).
Shares of Vectura Group PLC (VEC) traded down GBX 0.15 ($0.00) during trading hours on Thursday, reaching GBX 90.55 ($1.19). The company’s stock had a trading volume of 2,724,522 shares, compared to its average volume of 1,560,000. Vectura Group PLC has a 12 month low of GBX 86.50 ($1.14) and a 12 month high of GBX 166.97 ($2.20).
In other Vectura Group PLC news, insider Bruno Angelici bought 70,000 shares of the business’s stock in a transaction dated Tuesday, September 12th. The shares were acquired at an average price of GBX 99 ($1.30) per share, with a total value of £69,300 ($91,148.23). Also, insider Andrew Derodra bought 82,000 shares of the business’s stock in a transaction dated Thursday, September 7th. The shares were acquired at an average cost of GBX 90 ($1.18) per share, for a total transaction of £73,800 ($97,066.95). Insiders acquired a total of 152,456 shares of company stock worth $14,354,880 in the last ninety days.
About Vectura Group PLC
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.
Receive News & Ratings for Vectura Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.